Ultrasensitive in situ visualization of active glucocerebrosidase molecules

Nature Chemical Biology

Volumn 6, Issue 12, 2010, Pages 907-913

  Witte, Martin D ^a   Kallemeijn, Wouter W ^b   Aten, Jan ^b   Li, Kah Yee ^a   Strijland, Anneke ^b   Donker Koopman, Wilma E ^b   Van Den Nieuwendijk, Adrianus M C H ^a   Bleijlevens, Boris ^b   Kramer, Gertjan ^b,c   Florea, Bogdan I ^a   Hooibrink, Berend ^b   Hollak, Carla E M ^b   Ottenhoff, Roelof ^b   Boot, Rolf G ^b   Van Der Marel, Gijsbert A ^a   Overkleeft, Herman S ^a   Aerts, Johannes M F G ^b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

8 DEOXY 8 AZIDOCYCLOPHELLITOL; CELL AND TISSUE EXTRACTS; CYCLOPHELLITOL; FLUORESCENT DYE; GLUCOSYLCERAMIDASE; GLYCOSIDASE INHIBITOR; ISOFAGOMINE; KY 170; MDW 933; MDW 941; MIGLUSTAT; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL LABELING; CELL LYSATE; CELL SELECTION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ELECTROPHORESIS; ENDOPLASMIC RETICULUM; ENZYME REPLACEMENT; FIBROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE MICROSCOPY; GAUCHER DISEASE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR DOCKING; MOUSE; MUTANT; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SUBSTRATE REDUCTION THERAPY; SUPPLEMENTATION;

MUS;

EID: 78649302683     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.466     Document Type: Article

References (38)

1. Brady, R. O., Kanfer, J. N., Bradley, R. M. & Shapiro, D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 45, 1112-1115 (1966).
2. Grabowski, G. A. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372, 1263-1271 (2008).
3. Goker-Alpan, O. et al. The spectrum of Parkinsonian manifestations associated with glucocerebrosidase mutations. Arch. Neurol. 65, 1353-1357 (2008).
4. Van Weely, S. et al. Clinical genotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochim. Biophys. Acta 1096, 301-311 (1991).
5. Lachmann, R. H., Grant, I. R., Halsall, D. & Cox, T. M. Twin pairs showing discordance of phenotype in adult Gaucher's disease. QJM 97, 199-204 (2004).
6. Barton, N. W. et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324, 1464-1470 (1991).
7. Grabowski, G. A. et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122, 33-39 (1995).
8. Aerts, J. M., Hollak, C. E., Boot, R. G., Groener, J. E. & Maas, M. Substrate reduction therapy of glycosphingolipid storage disorders. J. Inherit. Metab. Dis. 29, 449-456 (2006).
9. Platt, F. M., Neises, G. R., Dwek, R. A. & Butters, T. D. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269, 8362-8365 (1994).
10. Jonsson, L. M. V. et al. Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. Eur. J. Biochem. 164, 171-179 (1987).
11. Ohashi, T. et al. Characterization of human glucocerebrosidase from different mutant alleles. J. Biol. Chem. 266, 3661-3667 (1991).
12. Sawkar, A. R. et al. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem. Biol. 12, 1235-1244 (2005).
13. Sawkar, A. R. et al. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. USA 99, 15428-15433 (2002).
14. Ron, I. & Horowitz, M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14, 2387-2398 (2005).
15. Mu, T. W. et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134, 769-781 (2008).
16. Steet, R. A. et al. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc. Natl. Acad. Sci. USA 103, 13813-13818 (2006).
17. Yu, Z., Sawkar, A. R., Whalen, L. J., Wong, C. H. & Kelly, J. W. Isofagomine- and 2, 5-anhydro-2, 5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J. Med. Chem. 50, 94-100 (2007).
18. Lieberman, R. L. et al. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat. Chem. Biol. 3, 101-107 (2007).
19. Kornhaber, G. J. et al. Isofagomine induced stabilization of glucocerebrosidase. ChemBioChem 9, 2643-2649 (2008).
20. Shen, J. S., Edwards, N. J., Hong, Y. B. & Murray, G. J. Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase. Biochem. Biophys. Res. Commun. 369, 1071-1075 (2008).
21. Liou, B. & Grabowski, G. A. Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease. Mol. Genet. Metab. 97, 65-74 (2009).
22. Rempel, B. P. & Withers, S. G. Covalent inhibitors of glycosidases and their applications in biochemistry and biology. Glycobiology 18, 570-586 (2008).
23. Atsumi, S., Nosaka, C., Iinuma, H. & Umezawa, K. Accumulation of tissue glucosylsphingosine in Gaucher-like mouse induced by the glucosylceramidase inhibitor cyclophellitol. Arch. Biochem. Biophys. 304, 302-304 (1993).
24. Hansen, F. G., Bundgaard, E. & Madsen, R. A short synthesis of (+)-cyclophellitol. J. Org. Chem. 70, 10139 (2005).
25. Brumshtein, B. et al. Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanisms of chemical chaperone action in Gaucher disease. J. Biol. Chem. 282, 29052 (2007).
26. Kacher, Y. et al. Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy. Biol. Chem. 389, 1361-1369 (2008).
27. Overkleeft, H. S. et al. Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J. Biol. Chem. 273, 26522-26527 (1998).
28. Arribas, J. C. et al. Differential mechanism-based labeling and unequivocal activity assignment of the two active sites of intestinal lactase/phlorizin hydrolase. Eur. J. Biochem. 267, 6996-7005 (2000).
29. Aerts, J. M. et al. Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. Biochim. Biophys. Acta 964, 303-308 (1988).
30. van Weely, S. et al. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease. J. Clin. Invest. 91, 1167-1175 (1993).
31. Chang, H. H., Asano, N., Ishii, S., Ichikawa, Y. & Fan, J. Q. Hydrophilic iminosugar active-sitespecific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients. FEBS J. 273, 4082-4092 (2006).
32. Rudensky, B. et al. Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease. Blood Cells Mol. Dis. 30, 97-99 (2003).
33. Gloster, T. M., Madsen, R. & Davies, G. J. Structural basis for cyclophellitol inhibition of a betaglucosidase. Org. Biomol. Chem. 5, 444-446 (2007).
34. Zechel, D. L. et al. Iminosugar glycosidase inhibitors: structural and thermodynamic dissection of the binding of isofagomine and 1-deoxynojirimycin to beta-glucosidases. J. Am. Chem. Soc. 125, 14313-14323 (2003).
35. Phenix, C. P. et al. Imaging of enzyme replacement therapy using PET. Proc. Natl. Acad. Sci. USA 107, 10842-10847 (2010).
36. Aerts, J. M. F. G. et al. A procedure for the rapid purification in high yield of human glucocerebrosidase using immunoaffinity chromatography with monoclonal antibodies. Anal. Biochem. 154, 655 (1986).
37. Boot, R. G. et al. Glucocerebrosidase genotype of Gaucher patients in The Netherlands: Limitations in prognostic value. Hum. Mutat. 10, 348 (1997).
38. Andersson, U., Butters, T. D., Dwek, R. A. & Platt, F. M. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem. Pharmacol. 59, 821 (2000).